|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Cancer Institute (NCI) |
|---|---|
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00040924 |
Purpose
RATIONALE: Screening tests may help doctors determine which patients are eligible for treatment on clinical trials.
PURPOSE: This clinical trial is screening patients with central nervous system tumors for participation in National Cancer Institute (NCI) clinical trials.
| Condition | Intervention |
|---|---|
|
Brain and Central Nervous System Tumors Lymphoma |
Other: cytology specimen collection procedure Other: physiologic testing |
| Study Type: | Interventional |
| Study Design: | Screening |
| Official Title: | Eligibility Screening Of Patients With Central Nervous System Tumors For The National Cancer Institute's (NCI) Clinical Research Protocols |
| Estimated Enrollment: | 3000 |
| Study Start Date: | April 2002 |
| Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
OBJECTIVES:
OUTLINE: Patients undergo various diagnostic procedures and clinical testing to determine eligibility for participation in NCI CNS tumor primary clinical research protocols. Patients undergo imaging scans; laboratory testing of blood, cerebrospinal fluid, bone marrow, urine, and other specimens as needed to determine protocol eligibility; and other specific organ function tests.
PROJECTED ACCRUAL: A maximum of 3,000 patients will be accrued for this study within 5 years.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Contacts and Locations| United States, Maryland | |
| Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office | Recruiting |
| Bethesda, Maryland, United States, 20892-1182 | |
| Contact: Clinical Trials Office - Warren Grant Magnusen Clinical Center 888-NCI-1937 | |
| Principal Investigator: | Howard A. Fine, MD | NCI - Neuro-Oncology Branch |
More Information
| Study ID Numbers: | CDR0000069420, NCI-02-C-0186 |
| Study First Received: | July 8, 2002 |
| Last Updated: | May 7, 2009 |
| ClinicalTrials.gov Identifier: | NCT00040924 History of Changes |
| Health Authority: | Unspecified |
|
childhood infratentorial ependymoma childhood low-grade cerebral astrocytoma childhood supratentorial ependymoma childhood craniopharyngioma childhood central nervous system germ cell tumor recurrent adult brain tumor ACTH-producing pituitary tumor prolactin-producing pituitary tumor growth hormone-producing pituitary tumor recurrent pituitary tumor TSH producing pituitary tumor nonfunctioning pituitary tumor adult brain stem glioma adult craniopharyngioma adult medulloblastoma |
adult meningioma adult glioblastoma pituitary basophilic adenoma prolactin secreting adenoma pituitary eosinophilic adenoma TSH secreting adenoma pituitary chromophobe adenoma childhood high-grade cerebral astrocytoma childhood oligodendroglioma adult anaplastic astrocytoma childhood choroid plexus tumor childhood grade I meningioma childhood grade II meningioma childhood grade III meningioma adult oligodendroglioma |
|
Lymphatic Diseases Neoplasms Neoplasms by Site Immunoproliferative Disorders Neoplasms by Histologic Type Immune System Diseases |
Nervous System Diseases Central Nervous System Neoplasms Lymphoproliferative Disorders Lymphoma Nervous System Neoplasms |
